Robeco Institutional Asset Management B.V. Cuts Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Robeco Institutional Asset Management B.V. trimmed its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 22.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,761 shares of the medical research company’s stock after selling 2,239 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Bio-Rad Laboratories were worth $2,550,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Van ECK Associates Corp boosted its holdings in shares of Bio-Rad Laboratories by 97.8% during the third quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock worth $436,861,000 after purchasing an additional 644,530 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Bio-Rad Laboratories by 1.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock valued at $147,583,000 after purchasing an additional 4,260 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Bio-Rad Laboratories by 3.9% during the third quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock valued at $84,571,000 after purchasing an additional 9,584 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Bio-Rad Laboratories during the third quarter valued at approximately $83,681,000. Finally, Mawer Investment Management Ltd. increased its position in shares of Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after acquiring an additional 84,237 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BIO shares. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and an average target price of $394.20.

Bio-Rad Laboratories Trading Down 2.1 %

Shares of Bio-Rad Laboratories stock opened at $353.34 on Tuesday. The company’s fifty day simple moving average is $340.61 and its 200-day simple moving average is $335.68. The stock has a market capitalization of $9.89 billion, a PE ratio of -12.93 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a 1-year low of $262.12 and a 1-year high of $387.99. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.